NBC Securities Inc. Decreases Stake in GSK plc (NYSE:GSK)

NBC Securities Inc. lessened its stake in shares of GSK plc (NYSE:GSK) by 1.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 32,461 shares of the pharmaceutical company’s stock after selling 471 shares during the quarter. NBC Securities Inc.’s holdings in GSK were worth $1,327,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Register Financial Advisors LLC bought a new stake in GSK in the 1st quarter worth $31,000. Ashton Thomas Private Wealth LLC purchased a new stake in shares of GSK during the second quarter worth about $37,000. Richardson Financial Services Inc. bought a new stake in shares of GSK in the fourth quarter worth about $40,000. PrairieView Partners LLC purchased a new position in GSK during the 2nd quarter valued at about $47,000. Finally, Triad Wealth Partners LLC purchased a new stake in GSK in the 2nd quarter worth approximately $49,000. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently issued reports on GSK. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a research note on Monday, July 8th. Citigroup upgraded shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. Barclays raised shares of GSK to a “hold” rating in a research note on Tuesday, August 27th. Jefferies Financial Group increased their price target on shares of GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday, July 2nd. Finally, Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $50.00.

Insider Activity at GSK

In other news, major shareholder Plc Gsk bought 2,791,930 shares of the firm’s stock in a transaction on Friday, September 27th. The stock was acquired at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.00% of the stock is currently owned by insiders.

GSK Trading Down 0.4 %

Shares of NYSE GSK opened at $38.96 on Wednesday. The stock has a market cap of $80.74 billion, a P/E ratio of 14.12, a price-to-earnings-growth ratio of 1.30 and a beta of 0.65. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.82 and a quick ratio of 0.54. GSK plc has a 1 year low of $33.67 and a 1 year high of $45.92. The firm has a 50-day moving average of $41.50 and a 200 day moving average of $41.32.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. The firm had revenue of $9.95 billion for the quarter, compared to analysts’ expectations of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. As a group, sell-side analysts expect that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, October 10th. Investors of record on Friday, August 16th were paid a $0.3843 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. The ex-dividend date of this dividend was Friday, August 16th. This represents a $1.54 dividend on an annualized basis and a yield of 3.95%. GSK’s payout ratio is presently 55.80%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.